Back to Search
Start Over
Ceria-based nanotheranostic agent for rheumatoid arthritis.
- Source :
-
Theranostics [Theranostics] 2020 Oct 25; Vol. 10 (26), pp. 11863-11880. Date of Electronic Publication: 2020 Oct 25 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Rheumatoid arthritis (RA) is an autoimmune disease that affects 1-2% of the human population worldwide, and effective therapies with targeted delivery for local immune suppression have not been described. We address this problem by developing a novel theranostic nanoparticle for RA and assessed its therapeutic and targeting effects under image-guidance. Methods: Albumin-cerium oxide nanoparticles were synthesized by the biomineralization process and further conjugated with near-infrared, indocyanine green (ICG) dye. Enzymatic-like properties and reactive oxygen species (ROS) scavenging activities, as well as the ability to reprogram macrophages, were determined on a monocyte cell line in culture. The therapeutic effect and systemic targeting potential were evaluated in collagen-induced arthritis (CIA) mouse model using optical/optoacoustic tomographic imaging. Results: Small nanotheranostics with narrow size distribution and high colloidal stability were fabricated and displayed high ROS scavenging and enzymatic-like activity, as well as advanced efficacy in a converting pro-inflammatory macrophage phenotype into anti-inflammatory phenotype. When administrated into affected animals, these nanoparticles accumulated in inflamed joints and revealed a therapeutic effect similar to the gold-standard therapy for RA, methotrexate. Conclusions: The inflammation-targeting, inherent contrast and therapeutic activity of this new albumin-cerium oxide nanoparticle may make it a relevant agent for assessing severity in RA, and other inflammatory diseases, and controlling inflammation with image-guidance. The design of these nanotheranostics will enable potential clinical translation as systemic therapy for RA.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)
- Subjects :
- Animals
Antirheumatic Agents chemistry
Antirheumatic Agents pharmacokinetics
Arthritis, Experimental diagnosis
Arthritis, Experimental immunology
Arthritis, Experimental pathology
Arthritis, Rheumatoid diagnosis
Arthritis, Rheumatoid immunology
Arthritis, Rheumatoid pathology
Cerium chemistry
Cerium pharmacokinetics
Collagen administration & dosage
Collagen immunology
Coloring Agents administration & dosage
Coloring Agents chemistry
Drug Compounding methods
Drug Monitoring methods
Freund's Adjuvant administration & dosage
Freund's Adjuvant immunology
Half-Life
Humans
Indocyanine Green administration & dosage
Indocyanine Green chemistry
Injections, Intra-Articular
Joints diagnostic imaging
Joints drug effects
Joints immunology
Joints pathology
Mice
Nanoparticles chemistry
Photoacoustic Techniques methods
RAW 264.7 Cells
Serum Albumin, Bovine chemistry
Severity of Illness Index
THP-1 Cells
Theranostic Nanomedicine methods
Tomography methods
Antirheumatic Agents administration & dosage
Arthritis, Experimental drug therapy
Arthritis, Rheumatoid drug therapy
Cerium administration & dosage
Nanoparticles administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1838-7640
- Volume :
- 10
- Issue :
- 26
- Database :
- MEDLINE
- Journal :
- Theranostics
- Publication Type :
- Academic Journal
- Accession number :
- 33204316
- Full Text :
- https://doi.org/10.7150/thno.49069